Khaja Misbahuddin, Lominadze George, Millerman Konstantin
Department of Medicine (Pulmonary and Critical Care Medicine), Bronx-Lebanon Hospital Center Affiliated with Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.
Division of Critical Care Medicine, New York Presbyterian-Lawrence Hospital Center Affiliated with Columbia University College of Physician and Surgeons, Bronxville, NY, USA.
Am J Case Rep. 2017 Jul 21;18:817-821. doi: 10.12659/ajcr.904695.
BACKGROUND Tapentadol is a centrally acting opioid analgesic, with a dual mode of action, as a norepinephrine reuptake inhibitor and an agonist of the μ-opioid receptor (MOR). Tapentadol is used for the management of musculoskeletal pain, and neuropathic pain associated with diabetic peripheral neuropathy. CASE REPORT A 32-year-old woman attended hospital for evaluation of an intractable headache. Computed tomography and magnetic resonance imaging of the brain were negative. She was found unresponsive in the bathroom on the day following hospital admission, and despite resuscitative measures, the patient died following cardiac arrest. Autopsy toxicology revealed significantly elevated levels of tapentadol, and bedside evidence suggested that the patient had self-administered this medication intravenously before her death. CONCLUSIONS We report a rare adverse effect of tapentadol causing respiratory depression leading to cardiac arrest. Medical examiners and forensic toxicologists should be aware of the toxicity of this novel opiate drug.
曲马多是一种中枢性阿片类镇痛药,具有双重作用模式,既是去甲肾上腺素再摄取抑制剂,又是μ-阿片受体(MOR)激动剂。曲马多用于治疗肌肉骨骼疼痛以及与糖尿病周围神经病变相关的神经性疼痛。病例报告:一名32岁女性因顽固性头痛入院评估。脑部计算机断层扫描和磁共振成像均为阴性。入院次日,她被发现于浴室中无反应,尽管采取了复苏措施,但患者最终因心脏骤停死亡。尸检毒理学显示曲马多水平显著升高,床边证据表明患者在死亡前曾静脉注射该药物。结论:我们报告了曲马多一种罕见的不良反应,即导致呼吸抑制进而引发心脏骤停。法医和法医毒理学家应知晓这种新型阿片类药物的毒性。